会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • PROTEINS
    • 蛋白质
    • WO2005066347A1
    • 2005-07-21
    • PCT/IB2004/004378
    • 2004-12-23
    • DANISCO A/SKELLET-SMITH, Anja HemmingsenLORENTSEN, Rikke, HøeghSØE, jørn, BorchMIKKELSON, Jørn, DalgaardKREIJ, Arno de
    • KELLET-SMITH, Anja HemmingsenLORENTSEN, Rikke, HøeghSØE, jørn, BorchMIKKELSON, Jørn, DalgaardKREIJ, Arno de
    • C12N15/54
    • C12N9/1029C12Y203/01085
    • The present invention relates to a method of producing a variant glycolipid acyltransferase enzyme comprising: (a) selecting a parent enzyme which is a glycolipid acyltransferase enzyme characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S; (b) modifying one or more amino acids to produce a variant glycolipid acyltransferase; (c) testing the variant glycolipid acyltransferase for transferase activity, an optionally hydrolytic activity, on a galactolipid substrate, and optionally a phospholipid substrate and/or optionally a triglyceride substrate; (d) selecting a variant enzyme with an enhanced activity towards galactolipids compared with the parent enzyme; and optionally (e) preparing a quantity of the variant enzyme. The present invention further relates to variant lipid acyltransferase enzyme characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues defined in set 2, set 4, set 6 or set 7.
    • 本发明涉及一种生产变体糖脂酰基转移酶的方法,包括:(a)选择亲糖基酶,其为糖脂酰基转移酶,其特征在于该酶包含氨基酸序列基序GDSX,其中X是一个或多个 以下氨基酸残基L,A,V,I,F,Y,H,Q,T,N,M或S; (b)修饰一个或多个氨基酸以产生变体糖脂酰基转移酶; (c)测试变体糖脂酰基转移酶对半乳糖脂底物和任选的磷脂底物和/或任选的甘油三酯底物的转移酶活性,任选水解活性; (d)与母体酶相比,选择对半乳糖脂增强活性的变体酶; 和(e)制备一定量的变体酶。 本发明还涉及变体脂质酰基转移酶,其特征在于该酶包含氨基酸序列基序GDSX,其中X是以下氨基酸残基中的一个或多个L,A,V,I,F,Y,H,Q ,T,N,M或S,并且其中所述变体酶与第2组,第4组,第6组或第7组中定义的任何一个或多个氨基酸残基与母体序列相比包含一个或多个氨基酸修饰。
    • 7. 发明申请
    • METHODS OF MODULATING SURFACTANT PRODUCTION
    • 调节表面活性剂生产的方法
    • WO02074907A3
    • 2002-11-21
    • PCT/US0205134
    • 2002-01-30
    • BAYER AGMASON ROBERT JAMESNEBEN STEVENECKART MICHAEL RLONGPHRE MALINDA
    • MASON ROBERT JAMESNEBEN STEVENECKART MICHAEL RLONGPHRE MALINDA
    • A61K38/00A61K48/00C12N9/10A01N43/04C07H21/04C07K1/00C12N1/20C12N5/00C12N15/00C12P21/06C12Q1/00
    • C12N9/1029A61K38/00A61K48/00C12Y203/01085
    • The present invention provides methods of modulating surfactant production using FAS polypeptides, and agonists or antagonists that are capable of modulating FAS activity. More particularly, the present invention encompasses the use of FAS polypeptides, or agonist or antagonist polypeptides capable of modulating FAS activity, for the treatment of a disease or clinical condition where surfactant production is relevant to the causation or treatment of the disease or clinical condition, such as lung diseases, including adult/infant respiratory distress syndrome, acute lung injury, chronic obstructive pulmonary disease (emphysema and chronic bronchitis), asthma, alveolar proteinosis, small airway disease and maintaining airway patency, and related pulmonary conditions. The present invention also encompasses pharmaceutical compositions containing the FAS polypeptides, or agonist or antagonist polypeptides capable of modulating FAS activity, and the use of such pharmaceutical compositions for the treatment of the above-mentioned diseases or clinical conditions.
    • 本发明提供了使用FAS多肽和能够调节FAS活性的激动剂或拮抗剂调节表面活性剂产生的方法。 更特别地,本发明包括FAS多肽或能够调节FAS活性的激动剂或拮抗剂多肽用于治疗疾病或临床病症的用途,其中表面活性剂产生与疾病或临床病症的因果关系或治疗相关, 如肺部疾病,包括成人/婴儿呼吸窘迫综合征,急性肺损伤,慢性阻塞性肺病(肺气肿和慢性支气管炎),哮喘,肺泡蛋白沉积症,小气道疾病和保持呼吸道通畅以及相关的肺部疾病。 本发明还包括含有FAS多肽或能够调节FAS活性的激动剂或拮抗剂多肽的药物组合物,以及这些药物组合物用于治疗上述疾病或临床症状的用途。
    • 8. 发明申请
    • METHODS OF MODULATING SURFACTANT PRODUCTION
    • 调节表面活性剂生产的方法
    • WO2002074907A2
    • 2002-09-26
    • PCT/US2002/005134
    • 2002-01-30
    • BAYER CORPORATIONMASON, Robert, JamesNEBEN, StevenECKART, Michael, R.LONGPHRE, Malinda
    • MASON, Robert, JamesNEBEN, StevenECKART, Michael, R.LONGPHRE, Malinda
    • C12N
    • C12N9/1029A61K38/00A61K48/00C12Y203/01085
    • The present invention provides methods of modulating surfactant production using FAS polypeptides, and agonists or antagonists that are capable of modulating FAS activity. More particularly, the present invention encompasses the use of FAS polypeptides, or agonist or antagonist polypeptides capable of modulating FAS activity, for the treatment of a disease or clinical condition where surfactant production is relevant to the causation or treatment of the disease or clinical condition, such as lung diseases, including adult/infant respiratory distress syndrome, acute lung injury, chronic obstructive pulmonary disease (emphysema and chronic bronchitis), asthma, alveolar proteinosis, small airway disease and maintaining airway patency, and related pulmonary conditions. The present invention also encompasses pharmaceutical compositions containing the FAS polypeptides, or agonist or antagonist polypeptides capable of modulating FAS activity, and the use of such pharmaceutical compositions for the treatment of the above-mentioned diseases or clinical conditions.
    • 本发明提供使用FAS多肽调节表面活性剂生产的方法,以及能调节FAS活性的激动剂或拮抗剂。 更具体地说,本发明包括使用能够调节FAS活性的FAS多肽或者能够调节FAS活性的激动剂或拮抗剂多肽用于治疗疾病或临床状况,其中表面活性剂的产生与疾病或临床状况的因果关系或治疗有关, 如肺部疾病,包括成人/婴儿呼吸窘迫综合征,急性肺损伤,慢性阻塞性肺病(肺气肿和慢性支气管炎),哮喘,肺泡蛋白沉积,小气道疾病和维持气道通畅以及相关的肺部疾病。 本发明还包括含有FAS多肽或能够调节FAS活性的激动剂或拮抗剂多肽的药物组合物,以及这些药物组合物用于治疗上述疾病或临床病症的药物组合物。